Endogenous insulin is the insulin your body produces naturally in the pancreas, as opposed to exogenous insulin, which is injected from an outside source. The distinction matters because these two forms of insulin enter the bloodstream differently, are cleared at different rates, and have somewhat different effects on your liver and muscles. Understanding endogenous insulin helps make sense of how diabetes develops, how it’s diagnosed, and why certain blood tests are ordered.
How Your Body Makes Insulin
Insulin is produced by beta cells in the pancreas. The process starts with a larger precursor molecule called preproinsulin, which contains 110 amino acids. Inside the beta cell, this precursor gets trimmed down in stages. First, a signal sequence is clipped off to create proinsulin. Then proinsulin folds into its proper three-dimensional shape and travels to another compartment of the cell, where it’s split into two pieces: insulin (51 amino acids, weighing about 5.8 kilodaltons) and a byproduct called C-peptide.
Both insulin and C-peptide are packaged into tiny storage granules inside the beta cell, waiting to be released. This packaging step is important because it means the body always produces insulin and C-peptide in equal amounts, a fact that becomes clinically useful for testing.
How Insulin Gets Released After a Meal
When blood sugar rises after eating, glucose enters beta cells through a transporter on the cell surface. The cell converts that glucose into energy, which triggers a chain reaction: potassium channels close, the cell membrane’s electrical charge shifts, and calcium channels open. The resulting surge of calcium inside the cell causes insulin granules to fuse with the cell wall and dump their contents into the bloodstream.
This release happens in two distinct waves. The first phase is rapid, occurring within 5 to 10 minutes, and involves a small pool of granules that are already stationed at the cell membrane, ready to go. The second phase is slower and more sustained, involving granules that need to be mobilized from deeper inside the cell. Only nutrients like glucose can trigger this second wave, which is why it’s considered a key marker of healthy beta cell function. Loss of the first-phase response is one of the earliest detectable signs that something is going wrong with insulin production.
What Endogenous Insulin Does in the Body
Once released, endogenous insulin travels first to the liver through the portal vein. Up to 80% of it is cleared during this initial pass through the liver, and its half-life in the portal circulation is only about 3 to 5 minutes. This “liver-first” delivery is a defining feature of endogenous insulin and has major metabolic consequences.
In the liver, insulin signals the organ to stop producing new glucose and start storing it as glycogen instead. In muscle tissue, insulin promotes the movement of glucose transporters to cell surfaces, allowing muscles to absorb glucose from the blood and store it as glycogen for later use. In fat tissue, insulin drives the conversion of excess energy into stored fat (a process called lipogenesis) while simultaneously blocking the breakdown of existing fat stores. Across all tissues, insulin also promotes protein building and inhibits protein breakdown. It is, fundamentally, a storage hormone: it tells the body that fuel is available and should be tucked away rather than released.
Endogenous vs. Exogenous Insulin
The most important difference between endogenous and injected insulin is the route of delivery. Endogenous insulin enters the portal vein and hits the liver first, where most of it is used up before it ever reaches the rest of the body. Injected insulin, by contrast, enters through the skin and reaches the general circulation first. This means it has a proportionally greater effect on muscle and fat tissue and a lesser initial effect on the liver.
Research comparing the two routes in humans confirmed that intraportally delivered insulin (mimicking the natural route) produces a greater hepatic effect and a smaller peripheral effect on glucose metabolism than insulin injected under the skin. This is one reason why even the best insulin therapy doesn’t perfectly replicate normal physiology. The liver, which is supposed to be the primary target, gets a relatively diluted signal from injected insulin, while peripheral tissues get a stronger-than-normal one.
How Endogenous Insulin Production Is Measured
Doctors rarely measure endogenous insulin directly, because insulin is cleared from the blood so quickly and variably that a single measurement isn’t very reliable. Instead, they measure C-peptide, the fragment that’s clipped off when proinsulin becomes insulin.
C-peptide is a better marker for several reasons. Its half-life is 20 to 30 minutes, compared to just 3 to 5 minutes for insulin, giving a wider and more stable testing window. The liver doesn’t significantly clear C-peptide the way it does insulin, so peripheral blood levels more accurately reflect what the pancreas actually produced. And in people taking insulin injections, C-peptide measurement avoids the problem of the test picking up injected insulin rather than the body’s own supply, since injected insulin contains no C-peptide.
C-peptide values between 200 and 600 pmol/L (0.6 to 1.8 ng/mL) are generally consistent with Type 1 diabetes or certain genetic forms of diabetes. Very low levels, below 80 pmol/L (0.24 ng/mL), indicate severe insulin deficiency and typically don’t need repeat testing. Values above 600 pmol/L (1.8 ng/mL) suggest the pancreas is still producing meaningful amounts of insulin, which helps distinguish Type 2 diabetes from late-onset Type 1. The 2025 American Diabetes Association standards recommend a random C-peptide sample taken within 5 hours of eating as a practical alternative to formal stimulation testing.
Endogenous Insulin in Type 1 and Type 2 Diabetes
Type 1 and Type 2 diabetes represent opposite ends of the endogenous insulin spectrum. In Type 1, the immune system destroys beta cells, eventually leading to little or no insulin production. C-peptide levels become low or undetectable as the disease progresses. People with Type 1 diabetes are completely dependent on exogenous insulin to survive.
Type 2 diabetes typically starts with insulin resistance, meaning the body’s cells don’t respond well to insulin’s signals. In the early stages, the pancreas compensates by producing more insulin than normal, so endogenous insulin levels are actually elevated. Over time, though, beta cells become exhausted and fail, and insulin production drops. This progressive decline is why some people with long-standing Type 2 diabetes eventually need insulin injections as well. In both types, the long-term result can look similar: reduced endogenous insulin output and dependence on external sources.
When Endogenous Insulin Is Too High
In rare cases, the body produces too much insulin on its own, a condition called endogenous hyperinsulinemic hypoglycemia. The most common cause is an insulinoma, a small tumor in the pancreas that secretes insulin independently of blood sugar levels, driving glucose dangerously low.
Diagnosis typically involves a supervised fasting test. If blood glucose drops to 3.0 mmol/L (about 54 mg/dL) or below while insulin remains at or above 3 μIU/mL and C-peptide is at or above 0.6 ng/mL, endogenous overproduction is confirmed. These thresholds have 100% sensitivity, meaning they catch virtually every case. Some centers use slightly higher cutoffs for better specificity. The key diagnostic logic is straightforward: if blood sugar is very low, the body should have stopped making insulin. If insulin and C-peptide are still measurably present, something is forcing the pancreas to keep producing it.
Fasting insulin levels in healthy adults generally fall below 15 mIU/L. Levels at or above that threshold, even without hypoglycemia, are considered hyperinsulinemia and may signal early metabolic dysfunction, including developing insulin resistance, well before blood sugar itself becomes abnormal.